Interaction of CpG-oligodeoxynucleotides with toll like receptor 9 induces apoptosis and modulates metaloproteinase-2 activity in human intestinal epithelium

Iranian Journal of Allergy, Asthma and Immunology

Volumn 6, Issue 3, 2007, Pages 107-114

  Khorramizadeh, Mohammad Reza ^a   Hosseinzadeh, Shahnaz ^a   Safavifar, Farnaz ^a   Saadat, Farshid ^a   Aalizadeh, Nastaran ^a   Falak, Reza ^a   Jadali, Zohre ^a   Pezeshki, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; CpG ODN; Cytotoxicity; HT 29; LPS; MMP 2; TLR9

Indexed keywords

CHLOROQUINE; CPG OLIGODEOXYNUCLEOTIDE; GELATINASE A; LIPOPOLYSACCHARIDE; METALLOPROTEINASE; TOLL LIKE RECEPTOR 9;

APOPTOSIS; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM; PROTEIN INTERACTION;

APOPTOSIS; HT29 CELLS; HUMANS; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; MATRIX METALLOPROTEINASE 2; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTOR 9;

EID: 35848958781     PISSN: 17351502     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol 2005; 141(2):298-306.
2. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, et al. Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 2005;6:1.
3. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168(9):4531-7.
4. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001; 166(4):2372-7.
5. Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii KJ, Verthelyi D, et al. CpG DNA: recognition by and activation of monocytes. Microbes Infect 2002; 4(9):897-901.
6. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000; 164(2):944-53.
7. Krieg Arthur M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-60.
8. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406(6797):782-7.
9. Inoue J, Aramaki Y. Cyclooxygenase-2 inhibition promotes enhancement of antitumor responses by transcutaneous vaccination with cytosine- phosphateguanosine-oligodeoxynucleotides and model tumor antigen. J Invest Dermatol 2007; 127(3):614-21.
10. Buhtoiarov IN, Sondel PM, Eickhoff JC, Rakhmilevich AL. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 2007; 120(3):412-23.
11. Akhtar M, Watson JL, Nazli A, McKay DM. Bacterial DNA evokes epithelial IL-8 produc-tion by a MAPK-dependent, NFkB independent pathway. FASEB Journal 2003;17(10):1319-21.
12. Bohnhorst J, Rasmussen T, Moen SH, Fløttum M, Knudsen L, Børset M, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20(6):1138-44.
13. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118(2):229-41.
14. Strober W, Fuss IJ, Nakamura K, Kitani A. Recent advances in the understanding of the induction and regulation of mucosal inflammation. J Gastroenterol 2003; 38( Suppl 15):55-8.
15. Strober W .Epithelial cells pay a Toll for protection. Nat Med 2004; 10(9):898-900
16. Jahrsdörfer B, Jox R, Mühlenhoff L, Tschoep K, Krug A, Rothenfusser S, et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72(1):83-92.
17. Bjersing JL, Tarkowski A, Collins LV. Anti-proliferative effects of phosphodiester oligodeoxynucleotides. Immunobiology 2004; 209(8):637-45.
18. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002; 101(5):415-22.
19. Shahverdi AR, Saadat F, Khorramizadeh MR, Iranshahi M, Khoshayand MR. Two matrix metalloproteinases inhibitors from Ferula persica var. persica. Phytomedicine 2006; 13(9-10):712-7.
20. Khorramizadeh MR, Aalizadeh N, Pezeshki M, Ghahary A, Zeraati H, Berahmeh A, et al. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters. Int J Urol 2005; 12(7):637-43.
21. Roberts TL, Sweet MJ, Hume DA, Stacey KJ. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 2005; 174(2):605-8.
22. Savidge TC, Shmakov AN, Walker-Smith JA, Phillips AD. Epithelial cell proliferation in childhood enteropathies. Gut 1996; 39(2):185-93.
23. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7(1):14-23.
24. Fischer SF, Rehm M, Bauer A, Höfling F, Kirschnek S, Rutz M, et al. Toll-like receptor 9 signaling can sensitize fibroblasts for apoptosis. Immunol Lett 2005; 97(1):115-22.
25. Papadopoulou S, Scorilas A, Arnogianaki N, Papapanayiotou B, Tzimogiani A, Agnantis N, et al. Expression of gelatinase-A (MMP-2) in human colon cancer and normal colon mucosa. Tumour Biol 2001; 22(6):383-9.
26. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res. 2006 Jul;4(7):437-47.
27. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007; 67(7):774-81.
28. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006; 54(6):526-35.
29. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20(6):1130-7.
30. Park Y, Lee SW, Sung YC. Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3′-OH kinase pathway. J Immunol 2002; 168(1):5-8.
31. Fischer SF, Rehm M, Bauer A, Höfling F, Kirschnek S, Rutz M, et al. Toll-like receptor 9 signaling can sensitize fibroblasts for apoptosis. Immunol Lett 2005; 97(1):115-22.
32. Yi AK, Peckham DW, Ashman RF, Krieg AM. CpG DNA rescues B cells from apoptosis by activating NFkB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol 1999; 11(12): 2015-24.